Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBI-03
- Development stage
- Preclinical
- Lead developer
- Fresh Tracks Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
BBI-03 is a preclinical, topically applied small-molecule inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), being developed for autoimmune and inflammatory skin diseases. As part of a DYRK1A inhibitor platform originally created by Voronoi and acquired by Brickell Biotech (now Fresh Tracks Therapeutics), BBI-03 is designed for local cutaneous delivery to modulate pathogenic immune signaling while limiting systemic exposure.[1][2][5][10] By selectively inhibiting DYRK1A, BBI-03 aims to restore immune balance in affected tissues, potentially addressing conditions such as atopic dermatitis and other dermatologic manifestations of immune dysregulation.[2][5][10]
02
Targets
DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)
Beyond the preview
Go deeper on BBI-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBI-03.